Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

Clinical Trial Details

This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T cell therapy participating in a previous Celgene-sponsored or Celgene alliance partner-sponsored study.

Participants who received at least one GM T cell infusion will be asked to enroll in this long-term follow-up upon either premature discontinuation from, or completion of the prior parent treatment protocol.
Participants will be on this study for up to 15 years. 

Key Eligibility: 

-Received at least one gene-modified (GM) T-cell infusion in a previous Celgene sponsored or - Celgene alliance partner-sponsored study, and have discontinued, or completed the post-treatment follow-up period in the parent treatment protocol, as applicable.

Detailed eligibility will be discussed when reaching out to the study team. 

Study contact by location

Upper East Side - Manhattan


Jerome Castaneda

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:






Open to Enrollment

Age Group